JPH037588A - Production of l-malic acid using fumarase - Google Patents
Production of l-malic acid using fumaraseInfo
- Publication number
- JPH037588A JPH037588A JP14146989A JP14146989A JPH037588A JP H037588 A JPH037588 A JP H037588A JP 14146989 A JP14146989 A JP 14146989A JP 14146989 A JP14146989 A JP 14146989A JP H037588 A JPH037588 A JP H037588A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- malic acid
- fumaric acid
- reaction
- fumarase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 title claims abstract description 36
- 229940116298 l- malic acid Drugs 0.000 title claims abstract description 17
- 108010036781 Fumarate Hydratase Proteins 0.000 title claims abstract description 7
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 40
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000001530 fumaric acid Substances 0.000 claims abstract description 20
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 20
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000011090 malic acid Nutrition 0.000 claims abstract description 19
- 239000006227 byproduct Substances 0.000 claims abstract description 12
- 244000068988 Glycine max Species 0.000 claims abstract description 4
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 4
- 235000009001 Quillaja saponaria Nutrition 0.000 claims description 3
- 241000694414 Sapindus saponaria Species 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 17
- 239000001384 succinic acid Substances 0.000 abstract description 11
- 244000005700 microbiome Species 0.000 abstract description 10
- 241000589500 Thermus aquaticus Species 0.000 abstract description 3
- 239000000047 product Substances 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 2
- 229930182490 saponin Natural products 0.000 abstract 2
- 150000007949 saponins Chemical class 0.000 abstract 2
- 240000003946 Saponaria officinalis Species 0.000 abstract 1
- 239000007795 chemical reaction product Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 229940099690 malic acid Drugs 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWYRUDPAALLKPX-UHFFFAOYSA-N 2,2-difluoro-n-methylethanamine;hydrochloride Chemical compound Cl.CNCC(F)F RWYRUDPAALLKPX-UHFFFAOYSA-N 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001749 Calcium fumarate Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241001092473 Quillaja Species 0.000 description 1
- 229930187719 Soyasaponin Natural products 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000019296 calcium fumarate Nutrition 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- -1 triterpenoid glycosides Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、微生物を活用したL−リンゴ酸の製法に関し
、詳しくはフマール酸をリンゴ酸に変換することのでき
る微生物の培養物をサボニンの存在下でフマール酸に接
触させることによって当該微生物のL−リンゴ酸生成能
力を高めるとともにコノ\り酸などの副生系を伴うこと
なくフマール酸からL−リンゴ酸を製造する方法に関す
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing L-malic acid using microorganisms, and more specifically, a culture of a microorganism capable of converting fumaric acid to malic acid is brought into contact with fumaric acid in the presence of sabonin. The present invention relates to a method for producing L-malic acid from fumaric acid without producing by-product systems such as cono-lyric acid while increasing the ability of the microorganism to produce L-malic acid.
(イ)産業上の利用分野
合成化学工業により安価に供給されるフマール酸を、本
発明の技術により、食品添加物質として異物有機酸コハ
ク酸を含まない純度の高いリンゴ酸の製造する技術を提
供する。(b) Industrial application field Provides a technology for producing high-purity malic acid that does not contain foreign organic acid succinic acid as a food additive by using the technology of the present invention from fumaric acid, which is supplied at low cost by the synthetic chemical industry. do.
(ロ)従来の技術
従来よりフマール酸からL−リンゴ酸を製造する方法は
特公昭37−4511号公報に代表される方法が知られ
る。また、単純に微生物とフマール酸の反応では不純物
の副生、たとえばコノ\り酸を伴う事がよく知られる。(b) Prior Art Conventionally, as a method for producing L-malic acid from fumaric acid, a method typified by Japanese Patent Publication No. 37-4511 is known. Furthermore, it is well known that a simple reaction between microorganisms and fumaric acid produces impurity by-products, such as conical acid.
精製工程の単純化を目的とする、これらコハク酸などの
副生を伴わない技術として胆汁酸またはその塩を含有す
るバイオリアクターによる方法など改良方法(特公昭5
2−31952号公報参照)、固定化微生物を界面活性
剤で活性化する方法(特公昭52−8396号、特公開
昭50−69289号公報参照)。これらの方法は充分
な目的を効率良く管理するには至らず、この課題を解決
しようとして提案された方法、すなはち副生反応を阻害
するために用いる胆汁酸は、動物の臓器より抽出され、
資源量、コスト、安定性などの面で実用には多くの問題
を抱えている。For the purpose of simplifying the purification process, improved methods such as a method using a bioreactor containing bile acids or their salts, which do not involve by-products such as succinic acid (Tokuko Kokō 5)
2-31952), and a method of activating immobilized microorganisms with a surfactant (see Japanese Patent Publications No. 52-8396 and Japanese Patent Publication No. 50-69289). These methods have not been able to efficiently manage the desired purpose, and the method proposed to solve this problem, namely, the bile acids used to inhibit by-product reactions, are extracted from animal organs. ,
There are many problems in practical use in terms of resource quantity, cost, stability, etc.
(ハ)発明が解決しようとする問題点
本発明者は、上記の従来技術をコストの低廉化へと向は
実用化の容易な副生反応を伴わず、フマール酸を効率良
<L−リンゴ酸へ変換する新規な技術を編み出すことを
目的とする。(c) Problems to be Solved by the Invention The present inventors aim to reduce the cost of the above-mentioned conventional technology by efficiently producing fumaric acid from L-apple without involving any by-product reactions that are easy to put into practical use. The aim is to develop a new technology to convert it into acid.
(ニ)問題点を解決する手段
本発明者らは、比較的低廉な天然有機化合物に、その資
源をもとめ、フマール酸よりコハク酸を生成する反応系
の阻害作用を広く試験検討した結果、植物起源のサボニ
ンが、低廉な有効作用であることを見いだした。これら
サボニンが微生物によりフマール酸からL−リンゴ酸を
生成する生物反応にコハク酸の副生に対し阻害作用のあ
る事実は従来知られておらず、本発明をもって最初とす
る。(d) Means for Solving the Problems The present inventors searched for resources in relatively inexpensive natural organic compounds, and as a result of extensive testing and investigation of their inhibitory effects on the reaction system that produces succinic acid from fumaric acid, they found that It was discovered that the original sabonin has an inexpensive and effective effect. The fact that these sabonins have an inhibitory effect on the by-product of succinic acid in the biological reaction of producing L-malic acid from fumaric acid by microorganisms has not been previously known, and this invention is the first such fact.
本発明において植物起源のサボニンを反応系に存在させ
る事は必須であり、これらは最近多くの市販食品添加物
質または医薬として容易に入手できる。本発明の実施に
際し用いるサボニンとしては、たとえば大豆より得られ
るツヤサボニン(Soyasaponin)、シャボン
の木(Qullaja 5aponaria)から抽出
されるキラヤサボニンなどトリテルペノイド系の配糖体
が低廉で、かつ有効な作用をしめす。また、コスト面で
実用的な問題はあるが、いわゆる漢方植物の抽出サボニ
ンたとえばカンゾウ(Glycyrhizae rad
ix)抽出物グリシリジン(Gly−cyrrhizi
n)、オタネニンジンのジンセッサイド(Ginsen
oside)、ミシマサイコの抽出配糖体サボニン(S
aikisaponin)などにも同様な作用が認めら
れる。従って、コハク酸副生を阻止する為には広(サボ
ニン群から適宜選択することができる。In the present invention, it is essential to have plant-derived sabonin present in the reaction system, and these are recently readily available as many commercially available food additives or medicines. As the sabonins used in the practice of the present invention, triterpenoid glycosides such as Soyasaponin obtained from soybeans and Quillaja sabonin extracted from Qullaja 5aponaria are inexpensive and exhibit effective effects. In addition, although there are practical problems in terms of cost, sabonins extracted from so-called Chinese herbal plants such as licorice (Glycyrhizae rad)
ix) Extract glycyridine (Gly-cyrrhizi)
n), Panax ginseng (Ginssen)
sabonin (S), an extracted glycoside of Mishimasaiko
A similar effect is also observed in drugs such as Aikisaponin). Therefore, in order to prevent the production of succinic acid by-products, it is possible to appropriately select from the sabonin group.
フマール酸からのL−リンゴ酸の生成に関与する微生物
は、たとえば特公昭44−1191号公報に記載される
フマラーゼ活性の強いミクロコツカス属、アグロモバク
テリウム属、コリネバクテリウム属、ブレビバクテリウ
ム属などの菌株をアメリカン・タイプカルチュアー・コ
レツクジョン(ATCC)、 財団法人・発酵研究所な
どの菌株保存機関より入手できるものから適宜選択出来
る。また、同明細書記載の方法に準じ、フマラーゼ活性
の強い菌株を、自然界よりスクーニングすることからも
現在では容易に実用的な菌株を取得できる。また、最近
、本発明者らにより高温条件を与えたスクリーニングに
より反応温度を高温にて行うサーマスRm株もATCC
25105など菌株同様に副反応を阻止できることも確
認されている。フマール酸の微生物によるしリンゴ酸へ
の変換は通常の培養法によれば簡単に進めることができ
るが、固定化微生物によるバイオリアクターによる酵素
反応でも効果的な結果がえられる。この場合の培養、反
応条件は、培養、反応液にサボニン類を添加する以外は
、公知の温度、pHに従う。 添加する植物抗酸化活性
物質の培養、反応液への添加量は、もちいる植物成分の
種類、純度により異なるが、たいがいの場合、主成分0
.05〜0.5g/dlの範囲で加える。この活性物質
は、市販きれるグーレードのものでも比較的安価である
が、それぞれの活性剤の開発で用いられた手法によって
植物より抽出して得られる部分精製したもので充分効果
を示す。Microorganisms involved in the production of L-malic acid from fumaric acid include, for example, Micrococcus spp., Agromobacterium spp., Corynebacterium spp., and Brevibacterium spp., which have strong fumarase activity and are described in Japanese Patent Publication No. 44-1191. Strains such as these can be selected as appropriate from those available from strain repositories such as the American Type Culture Collection (ATCC) and the Fermentation Research Institute. Furthermore, by screening strains with strong fumarase activity from nature according to the method described in the same specification, practical strains can now be easily obtained. In addition, recently, the present inventors screened ATCC under high temperature conditions and found that the Thermus Rm strain, which performs the reaction at a high temperature, was
It has also been confirmed that it can prevent side reactions like strains such as 25105. The conversion of fumaric acid to malic acid by microorganisms can be easily carried out by conventional culture methods, but effective results can also be obtained by enzymatic reaction using immobilized microorganisms in a bioreactor. The culture and reaction conditions in this case follow known temperatures and pH, except for adding sabonins to the culture and reaction solution. The amount of the plant antioxidant active substance added to the culture and reaction solution varies depending on the type and purity of the plant component used, but in most cases, the main component is 0.
.. Add in a range of 0.05 to 0.5 g/dl. This active substance is relatively inexpensive even if it is a commercially available gourade, but it is sufficiently effective if it is partially purified and extracted from plants using the methods used to develop each active agent.
以下に実施例をもって本発明の実施の態様を説明するが
、これらは単なる例示であって、本発明を何んら制限す
るものではない。Embodiments of the present invention will be described below with reference to Examples, but these are merely illustrative and do not limit the present invention in any way.
実施例1゜
グルコース1.0g/<II、尿素0.2g/di、リ
ン酸−カリ0、2g/di、コーンステイープリカー0
.5g/di、炭酸カルシュラムで中和したフマール酸
10g/di、消泡剤アデカノールLG−109(旭電
化:商品名)0.5ml/diより成る溶液100m1
を500m1容三角フラスコに仕込み、これにブレビバ
クテリウム・アンモニアゲネス(Brevibacte
rium ammoniagenes)IAM1645
菌株を接種してpH7,0、温度30’Cで回転通気培
養をおこなった。培養開始後10時間でキラニンP−2
0(商品名コシャボンの木すポニン:丸善化成製) 1
20mg/dQになるよう添加し、さらに30時間培養
をつずけた。培養液中のフマール酸はほとんどL−リン
ゴ酸に転換され、カルシュム塩として回収出来たが、得
られたカルシュム塩の中には全くコハク酸は確認されな
かった。発酵終了液100m1中のL−リンゴ酸の生成
量は11、30gであった。なを、対象試験どしてサン
フードを添加しなかった場合の培養を並行した場合、こ
の培養液中のコハク酸の生成量は0.58/dlであり
、明らかにポリフェノール系酸化防止剤が副反応を防止
していることも確認出来た。Example 1゜Glucose 1.0g/<II, urea 0.2g/di, phosphoric acid-potassium 0, 2g/di, cornstarch liquor 0
.. 5 g/di, fumaric acid neutralized with calcium carbonate 10 g/di, and antifoaming agent Adekanol LG-109 (Asahi Denka: trade name) 0.5 ml/di.
was placed in a 500 m Erlenmeyer flask, and Brevibacterium ammoniagenes was added to this.
rium ammoniagenes) IAM1645
The bacterial strain was inoculated and cultured under rotary aeration at pH 7.0 and temperature 30'C. Chiranin P-2 10 hours after the start of culture
0 (Product name Koshabon no Kisuponin: manufactured by Maruzen Kasei) 1
The solution was added at a concentration of 20 mg/dQ, and the culture was continued for an additional 30 hours. Most of the fumaric acid in the culture solution was converted to L-malic acid and recovered as calcium salt, but no succinic acid was observed in the calcium salt obtained. The amount of L-malic acid produced in 100 ml of the fermentation-finished liquid was 11.30 g. Furthermore, when culturing was performed in parallel without adding Sunfood in the target test, the amount of succinic acid produced in this culture solution was 0.58/dl, which clearly indicates that polyphenol antioxidants It was also confirmed that side reactions were prevented.
実施例2゜
種菌としてサーマス・アクアティクス(Thermus
aquaticus)ATCC25105菌株を使用し
た。Example 2゜ Thermus aquaticus (Thermus aquaticus) was used as the seed fungus.
aquaticus) ATCC25105 strain was used.
培地としては尿素0,2g/di、KH2PO−0,2
g/dl、硫酸マグネシュウム50mg/dl、コーン
ステイープリカーIg/dl、フマール酸カルシュウム
0.5g/dLブドウ糖2、2g/diを含みpH7,
0に調製した。発酵は30°Cにて24時間、上記培地
10cを仕込んだ2Of2容ジヤーフアフアーメンター
にて培養した。得られた培養液にマール酸200g、炭
酸カルシュウム181gおよび大豆サボニンピュア(商
品名:稲畑工業製)2.0gを投入し35°Cにて24
時間撹拌360r、 p、 m条件のもとで反応をおこ
ない全量を冷蔵庫内に一夜放置し、濾過してI、−リン
ゴ酸カルシウム粗結晶255gを得た。この結晶には副
生コハク酸は確認できなかった。As a medium, urea 0.2g/di, KH2PO-0.2
g/dl, magnesium sulfate 50 mg/dl, cornstarch liquor Ig/dl, calcium fumarate 0.5 g/dL glucose 2, pH 7,
It was adjusted to 0. Fermentation was carried out at 30°C for 24 hours in a 2Of2 jar fermenter containing the above medium 10c. 200 g of maric acid, 181 g of calcium carbonate, and 2.0 g of Soybean Savonin Pure (trade name: manufactured by Inabata Kogyo) were added to the obtained culture solution, and the mixture was incubated at 35°C for 24 hours.
The reaction was carried out under stirring conditions of 360 r, p, m for hours, and the entire amount was left in a refrigerator overnight and filtered to obtain 255 g of crude crystals of calcium I,-malate. No by-product succinic acid was confirmed in this crystal.
実施例3゜
発酵菌株としてミクロバクテリウム・アンモニアフルム
(Microbacterium ammoniaph
ilum)ATCC13345株を用い、実施例2に準
じ培養し、さらに反応液組成のうちサボニンとしてシャ
ボンの木より製剤化したイコニン(商品名:田代興業製
180mg/di、セチルビリムシニュームクロライド
10mg/dlを用いる以外、同じ条件下で反応をおこ
なった。得られたI、−リンゴ酸カルシュームは265
gで、通常の分析法では副生コハク酸は認められなかっ
た。Example 3 Microbacterium ammoniaph as a fermentation strain
Ilum) ATCC 13345 strain was cultured according to Example 2, and in the reaction solution composition, sabonin was formulated from soap tree (trade name: Tashiro Kogyo 180 mg/di, cetyl bilimcinium chloride 10 mg/dl). The reaction was carried out under the same conditions except that the obtained calcium I,-malate was 265
g, and no by-product succinic acid was observed using conventional analytical methods.
実施例4゜
実施例1により培養して得られたフマラーセ源ブレビバ
クテリウム・アンモニアゲネス(Brebibacte
rium ammoniagenes)lFO1645
菌体を生理食塩水で2回洗浄したちの25g、およびイ
コニン800mgをカルボキシル化キトサン水溶液中に
練り込み接触させて原液とし、孔径0.3mmのノズル
から3%塩化コバルトの混合水溶液中に滴下速度3ml
/minで投入し固定化菌体を得た。 この固定化菌体
を10Q容固定型バイオリアクターに全量セットしとし
た。ポンプにて0.02%セチルビリジニュウムクロラ
イドを含む10g/12フマール酸pl(7,0中和溶
液を10mQ/minの流速で連続流加しL−リンゴ酸
への反応を行わせた。得られた反応液1f2に炭酸カル
シューム14gを加え全容を173に濃縮し、−夜冷部
し、晶析したし一すンゴ酸カルシュウムを10.8g骨
分離収した。得られた結晶の副生コノ\り酸は定量分析
では確認出来ない範囲であった。Example 4 The fumarase source Brebibacterium ammoniagenes (Brebibacterium ammoniagenes) obtained by culturing in Example 1
rium ammoniagenes)lFO1645
After washing the bacterial cells twice with physiological saline, 25 g and 800 mg of Iconine were kneaded into an aqueous solution of carboxylated chitosan to make a stock solution, which was then dropped into a mixed aqueous solution of 3% cobalt chloride through a nozzle with a pore size of 0.3 mm. Speed 3ml
/min to obtain immobilized bacterial cells. The entire amount of the immobilized bacterial cells was set in a 10Q capacity immobilized bioreactor. 10 g/12 fumaric acid pl (7,0 neutralized solution) containing 0.02% cetyl pyridinium chloride was continuously added at a flow rate of 10 mQ/min using a pump to react to L-malic acid. 14 g of calcium carbonate was added to the resulting reaction solution 1f2, and the total volume was concentrated to 173 ml, and the mixture was cooled overnight. 10.8 g of crystallized calcium chloride was isolated from the bones. Raw acid was in a range that could not be confirmed by quantitative analysis.
(発明の効果)
本発明技術により植物起源配糖体サボニンの存在のもと
でフマラーゼによる酵素反応を管理することで、コハク
酸の副生をみることなくL−リンゴ酸の製造が実施出来
る。(Effects of the Invention) By controlling the enzymatic reaction by fumarase in the presence of the plant-derived glycoside sabonin, L-malic acid can be produced without producing succinic acid as a by-product.
Claims (2)
る微生物培養物をサボニンの存在のもとでフマール酸に
作用させ、コハク酸の副生を伴わないフマラーゼによる
L−リンゴ酸の製造方法。(1) A method for producing L-malic acid using fumarase, which does not involve the by-product of succinic acid, by allowing a microbial culture capable of converting fumaric acid to L-malic acid to act on fumaric acid in the presence of sabonin. .
ボニンの存在下で微生物培養物とフマール酸を作用させ
るL−リンゴ酸の製造方法。(2) A method for producing L-malic acid in which a microbial culture and fumaric acid are reacted in the presence of sabonin extracted from soybeans or soap trees.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14146989A JPH037588A (en) | 1989-06-03 | 1989-06-03 | Production of l-malic acid using fumarase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14146989A JPH037588A (en) | 1989-06-03 | 1989-06-03 | Production of l-malic acid using fumarase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH037588A true JPH037588A (en) | 1991-01-14 |
Family
ID=15292610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14146989A Pending JPH037588A (en) | 1989-06-03 | 1989-06-03 | Production of l-malic acid using fumarase |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH037588A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007247278A (en) * | 2006-03-16 | 2007-09-27 | Shimizu Corp | Damping damper |
-
1989
- 1989-06-03 JP JP14146989A patent/JPH037588A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007247278A (en) * | 2006-03-16 | 2007-09-27 | Shimizu Corp | Damping damper |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101046905B1 (en) | Method for obtaining basic amino acid hydrochloride crystals | |
| US2749279A (en) | Enzymatic production of l-glutamic acid | |
| JPH037588A (en) | Production of l-malic acid using fumarase | |
| JPH03130084A (en) | Production of trehalose | |
| JPH037587A (en) | Production of l-malic acid | |
| JPS5937076B2 (en) | Fermentation method Vitamin B↓1↓2 manufacturing method | |
| US3058888A (en) | Process for producing alpha-isoleucine | |
| CN101649344A (en) | Biological preparation technology of D-lactamine | |
| US2798839A (en) | Production of l-glutamic acid | |
| JPS5836393A (en) | Preparation of abscisic acid by fermentation method | |
| CN113511936A (en) | Method for producing calcium lactate-based secondary element water-soluble fertilizer | |
| US4659661A (en) | Process for the preparation of fermentation broth for coenzyme B12 and other corrinoid production | |
| US4752584A (en) | Process for the production of inoculum for anaerobic fermentation of coenzyme B12 | |
| US3061522A (en) | Process for the production of demethyltetracyclines | |
| JP2002281993A (en) | Method for producing shikimic acid | |
| JP3030896B2 (en) | WB968 substance group and production method thereof | |
| SU1711788A1 (en) | Method for culturing lactic acid and propionic acid bacteria | |
| NIMI et al. | Effect of arginine on gramicidin S biosynthesis by Bacillus brevis | |
| JPH02291281A (en) | Preparation of 1,2-dihydroxy-1,2-dihydro-7-methylnaphthalene | |
| CN120591362A (en) | A method for producing vitamin B12 by fermenting Propionibacterium sieversii | |
| JPS63295A (en) | Production of nicotinamide adenine dinucleotide | |
| CN120591363A (en) | A method for increasing vitamin B12 production by ultrasound-assisted fermentation | |
| SU183581A1 (en) | METHOD OF MANUFACTURE / -LMZINA | |
| SU448653A3 (en) | The method of obtaining antibiotic | |
| JPS58146285A (en) | Preparation of coenyzme q10 |